Notice of Corporate Officer Change
June 3, 2024, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) today announced the following executive management change, effective June 3rd. Dr. Shawn Xiang will assume the new position of Corporate Officer, Head of China Business.
Executive management change effective June 3rd, 2024
| Name | New Title |
|---|---|
| Shawn Xiang | Corporate Officer Head of China Business |
| Name | New position | Current position |
|---|---|---|
| Rie Nakajima | Corporate Officer Chief Operating Officer | Corporate Officer Chief Operating Officer Head of China Business |
Biography: Shawn Xiang
Dr. Xiang joined Santen on June 3rd, 2024 as Corporate Officer, Head of China Business. In this role, he is responsible for leading business in the China market, including the formulation of business and sales strategies, portfolio management, and commercial excellence in the region. Dr. Xiang brings 17 years of business management consulting and leadership experience in the pharmaceutical and healthcare industries. We aim to enhance our corporate value through further growth and development of our China business by leveraging his extensive business experience, especially in China.
Dr. Xiang began his career as a consultant at McKinsey & Company in the USA, focusing on several projects on pharmaceutical and medical device companies. Since 2011, he held roles at Novartis Global in Switzerland as Director of Global Pharma Strategy and since 2012, he held roles at Novartis China as Franchise Head of Bone Disease and Franchise Head of Respiratory Disease. Since 2016, Dr. Xiang was the General Manager for the Greater China and Emerging Asia Region at Abbott Diabetes Care, where he oversaw the launch of new products in several key markets. Most recently, Dr. Xiang served as the CEO of RareStone Group, where he introduced strategies that led to rapid drug approvals, market access breakthroughs, and the creation of a rare disease ecosystem.
He holds a bachelor's degree in engineering from Peking University and a doctorate in engineering from Yale University.
About Santen
As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “Tenki ni sanyo suru,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”
For more information, please visit Santen’s website https://www.santen.com/en.
Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com
Official SNS
